Large Molecule Drug Substance CDMO Market Size Worth USD 108.18 Billion by 2034 | CAGR: 7.64%
The Large molecule drug substance CDMO market size is expected to reach USD 108.18 Billion by 2034, according to a new study by Polaris Market Research. The report “Large Molecule Drug Substance CDMO Market Share, Size, Trends, Industry Analysis Report: By Product (Biologics and Biosimilar), By Service, By Source, By End User, and By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Large molecule drug substance CDMO is a service that helps in outsourcing development and manufacturing of biologics such as monoclonal antibodies and biosimilars. It gives access to pharmaceutical companies to a specialized infrastructure, KNOW-HOW and regulatory support for an efficient and effective production. The market growth is attributed to the increasing approvals of biologic drugs globally, rising healthcare expenditure, increasing share of biologics in total pharmaceutical spending, increased adoption of biosimilars, and growing investments in next-generation bioprocessing solutions.
Large Molecule Drug Substance CDMO Market Report Highlights
- By product, the biologics segment held the largest share on the back of high demand for monoclonal antibodies (mAbs) and more complex proteins.
- By service, contract manufacturing held the largest share in the market due to the demand for mass production.
- On the basis of source, the mammalian systems market led the market for complex, high-quality biologics.
- By end user, the biopharmaceutical companies segment held a potential share as they have extensive pipelines of biologics, and large-scale production. North America dominated in 2024 due to mature biopharma ecosystem and continued biologic approvals.
- The Asia Pacific region experienced rapid growth owing to increasing investments in biologics manufacturing in China and India and supportive government policies.
- A few global key market players include Thermo Fisher Scientific Inc., Eurofins Scientific SE, Wuxi Biologics, Samsung Biologics Co., Ltd., Catalent, Inc., AGC Biologics, Boehringer Ingelheim International GmbH, FUJIFILM Diosynth Biotechnologies, Lonza Group, Recipharm AB, Siegfried Holding AG, and Rentschler Biopharma SE.
Request a free sample copy or read the full market insights : Large Molecule Drug Substance CDMO Market Report
Polaris Market Research has segmented the market report on the basis of product, service, source, end user, and region:
By Product Outlook (Revenue, USD Billion, 2020–2034)
- Biologics
- Biosimilar
By Service Outlook (Revenue, USD Billion, 2020–2034)
- Contract Manufacturing
- Clinical
- Commercial
- Contract Development
- Cell Line Development
- Process Development
By Source Outlook (Revenue, USD Billion, 2020–2034)
- Mammalian
- Microbial
- Others
By End User Outlook (Revenue, USD Billion, 2020–2034)
- Biopharmaceutical Companies
- Biotechnology Companies
- Academic and Research Institutes
By Regional Outlook (Revenue, USD Billion, 2020–2034)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
